<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960934</url>
  </required_header>
  <id_info>
    <org_study_id>5442-001</org_study_id>
    <secondary_id>2009-012926-35</secondary_id>
    <nct_id>NCT00960934</nct_id>
  </id_info>
  <brief_title>A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001)</brief_title>
  <official_title>A Phase IIb, Randomized, Placebo-Controlled, Dose-Ranging Study of MK-5442 in the Treatment of Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to identify an appropriate dose of

      MK-5442 that produced an osteoanabolic effect without causing hypercalcemia in postmenopausal
      women with osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amendment 4 of the protocol changed the duration of the study from 2 years to 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Least Squares (LS) Mean Percent Change From Baseline to Month 6 in Lumbar Spine Areal Bone Mineral Density (aBMD)</measure>
    <time_frame>Baseline (BL) and Month 6</time_frame>
    <description>Dual Energy X-ray Absorptiometry (DXA) was used to assess and measure aBMD of the lumbar spine. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Total Serum Calcium Levels Outside the Pre-defined Limits of Change</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>Normal serum calcium level is 8-10 mg/dL (2-2.5 mmol/L) with some interlaboratory variation in the reference range, and hypercalcemia is defined as a serum calcium level greater than 10.5 mg/dL (&gt;2.5 mmol/L).
Based on these references, ≥10.6 mg/dL was predefined in this study as the cut-off for the normal limits of change. Participants with calcium levels ≥10.6 mg/dL were considered as having a &quot;Tier 1&quot; safety event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Albumin-Corrected Calcium Levels Outside the Pre-defined Limits of Change</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>Albumin-Corrected Calcium = ([4 - plasma albumin in g/dL] × 0.8 + serum calcium).
≥10.6 mg/dL was predefined in this study as the cut-off for the normal limits of change. Participants with albumin-corrected calcium levels ≥10.6 mg/dL were considered as having a &quot;Tier 1&quot; safety event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Kidney Stones</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>Evidence of kidney stone(s) was considered an event of interest and was prespecified as a &quot;Tier 1&quot; safety event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Bone Neoplasms</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>Evidence of bone neoplasm(s) was considered an event of interest and was prespecified as a &quot;Tier 1&quot; safety event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LS Mean Percent Change From Baseline to Month 6 in Total Hip aBMD</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>DXA was used to assess and measure aBMD of the total hip. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Percent Change From Baseline to Month 6 in Femoral Neck aBMD</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>DXA was used to assess and measure aBMD of the femoral neck. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Percent Change From Baseline to Month 6 in Trochanter aBMD</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>DXA was used to assess and measure aBMD of the trochanter. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Percent Change From Baseline to Month 6 in Total Body aBMD</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>DXA was used to assess and measure aBMD of the total body. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Percent Change From Baseline to Month 6 in Distal One-third Forearm Areal BMD</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>DXA was used to assess and measure aBMD of the distal 1/3 forearm. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Percent Change From Baseline to Month 6 in Trabecular Volumetric BMD of the Hip</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Quantitative computed tomography (QCT) technology was used to assess and measure bone mineral content volumetrically (ie, in grams of tissue per centimeter of tissue cubed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Percent Change From Baseline to Month 6 in Trabecular Volumetric BMD of the Lumbar Spine</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Quantitative computed tomography (QCT) technology was used at baseline and periodically through out the study to assess and measure bone mineral content volumetrically (ie, in grams of tissue per centimeter of tissue cubed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Percent Change From Baseline to Month 6 in the Ratio of Urinary N-Telopeptides of Type I Collagen to Creatinine (u-NTx/Cr)</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>The ratio of u-NTx to Cr is a biomarker for bone resorption. It is measured in the serum in units of nanomoles (nm) of bone collagen equivalents (BCE)/millimoles of creatinine (Cr).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Percent Change From Baseline to Month 6 in Serum C-Terminal Telopeptide Collagen I (s-CTx)</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>C-Terminal Telopeptide Collagen I is used as a serum-marker of bone resorption in the assessment of osteoporosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Percent Change From Baseline to Month 6 in Serum Bone-Specific Alkaline Phosphatase (s-BSAP)</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Bone Specific Alkaline Phosphatase is a biomarker of bone formation and is measured in units of microgram (μg)/liter (L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Percent Change From Baseline to Month 6 in Serum Procollagen Type I N-Terminal Propeptide (P1NP)</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Measurement of P1NP appears to be a sensitive marker of bone formation rate in the assessment of osteoporosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Percent Change From Baseline to Month 6 in Serum Osteocalcin</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Serum osteocalcin is a biomarker of bone formation and is measured using units of nanograms (ng) / milliliter (mL).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">383</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>MK-5442 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-5442 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-5442 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-5442 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-5442 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-5442</intervention_name>
    <description>MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.</description>
    <arm_group_label>MK-5442 2.5 mg</arm_group_label>
    <arm_group_label>MK-5442 5 mg</arm_group_label>
    <arm_group_label>MK-5442 7.5 mg</arm_group_label>
    <arm_group_label>MK-5442 10 mg</arm_group_label>
    <arm_group_label>MK-5442 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose-matched oral placebo to MK-5442</description>
    <arm_group_label>MK-5442 2.5 mg</arm_group_label>
    <arm_group_label>MK-5442 5 mg</arm_group_label>
    <arm_group_label>MK-5442 7.5 mg</arm_group_label>
    <arm_group_label>MK-5442 10 mg</arm_group_label>
    <arm_group_label>MK-5442 15 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3, two 400 IU tablets daily throughout the study.</description>
    <arm_group_label>MK-5442 2.5 mg</arm_group_label>
    <arm_group_label>MK-5442 5 mg</arm_group_label>
    <arm_group_label>MK-5442 7.5 mg</arm_group_label>
    <arm_group_label>MK-5442 10 mg</arm_group_label>
    <arm_group_label>MK-5442 15 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium carbonate</intervention_name>
    <description>Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.</description>
    <arm_group_label>MK-5442 2.5 mg</arm_group_label>
    <arm_group_label>MK-5442 5 mg</arm_group_label>
    <arm_group_label>MK-5442 7.5 mg</arm_group_label>
    <arm_group_label>MK-5442 10 mg</arm_group_label>
    <arm_group_label>MK-5442 15 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal for at least 5 years

          -  No history of fragility fracture, unless participant is not willing to take marketed
             osteoporosis therapy or is not a candidate for marketed osteoporosis therapy

          -  Agrees not to use medications for osteoporosis except medications associated with the
             study

          -  Areal bone mineral density (BMD) T-score &lt;-2.5 at one or more of the following 4 BMD
             sites: total hip, femoral neck, trochanter, or lumbar spine and is ≥ -3.5 at all 4 BMD
             sites. Participants unwilling to take or ineligible for marketed osteoporosis therapy
             may have one or more areal BMD T-scores of &lt; -3.5

        Exclusion Criteria:

          -  Unable to undergo dual-energy X-ray absorptiometry (DXA) scan due to obesity (ie,
             weight &gt;250 lbs)

          -  Use of oral bisphosphonates in the 6 months prior to study screening, for more than 3
             months in the past 2 years, or lifetime use of more than 6 months

          -  Use of intravenous bisphosphonates, strontium, or growth hormone at any time

          -  Use of phenytoin or heparin within 2 weeks prior to Visit 1; use of raloxifene within
             6 months prior to Visit 1

          -  Use of pioglitazone or rosiglitazone at study screening

          -  Use of estrogen ± progestin, in any form other than vaginal or topical application,
             for 6 months prior to Study Visit 1

          -  Prior total thyroidectomy

          -  Human immunodeficiency virus (HIV)- positive or acquired immune deficiency syndrome
             (AIDS)-related illness

          -  History of malignant cancer within 5 years of study screening, except for certain skin
             or cervical cancers

          -  History of Paget's disease and/or kidney stones

          -  An active user of any illicit drug

          -  History of or active alcohol abuse

          -  Participated in an investigational drug study within the past 30 days
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Halse J, Greenspan S, Cosman F, Ellis G, Santora A, Leung A, Heyden N, Samanta S, Doleckyj S, Rosenberg E, Denker AE. A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2014 Nov;99(11):E2207-15. doi: 10.1210/jc.2013-4009. Epub 2014 Aug 28.</citation>
    <PMID>25166719</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <results_first_submitted>August 14, 2012</results_first_submitted>
  <results_first_submitted_qc>October 2, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2012</results_first_posted>
  <last_update_submitted>February 1, 2015</last_update_submitted>
  <last_update_submitted_qc>February 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>MK-5442</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>383 participants were randomized on study and 380 participants were treated on study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MK-5442 2.5 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="P2">
          <title>MK-5442 5 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="P3">
          <title>MK-5442 7.5 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="P4">
          <title>MK-5442 10 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="P5">
          <title>MK-5442 15 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="64"/>
                <participants group_id="P6" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Number Treated</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="62">1 participant was randomized but not treated</participants>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="63">1 participant was randomized but not treated</participants>
                <participants group_id="P6" count="63">1 participant was randomized but not treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="64"/>
                <participants group_id="P6" count="64"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="49"/>
                <participants group_id="P6" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-5442 2.5 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="B2">
          <title>MK-5442 5 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="B3">
          <title>MK-5442 7.5 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="B4">
          <title>MK-5442 10 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="B5">
          <title>MK-5442 15 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="64"/>
            <count group_id="B4" value="64"/>
            <count group_id="B5" value="64"/>
            <count group_id="B6" value="64"/>
            <count group_id="B7" value="383"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" spread="6.3"/>
                    <measurement group_id="B2" value="67.3" spread="6.5"/>
                    <measurement group_id="B3" value="67.4" spread="6.0"/>
                    <measurement group_id="B4" value="67.8" spread="6.4"/>
                    <measurement group_id="B5" value="66.5" spread="5.4"/>
                    <measurement group_id="B6" value="67.6" spread="6.7"/>
                    <measurement group_id="B7" value="67.2" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="64"/>
                    <measurement group_id="B7" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Least Squares (LS) Mean Percent Change From Baseline to Month 6 in Lumbar Spine Areal Bone Mineral Density (aBMD)</title>
        <description>Dual Energy X-ray Absorptiometry (DXA) was used to assess and measure aBMD of the lumbar spine. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
        <time_frame>Baseline (BL) and Month 6</time_frame>
        <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares (LS) Mean Percent Change From Baseline to Month 6 in Lumbar Spine Areal Bone Mineral Density (aBMD)</title>
          <description>Dual Energy X-ray Absorptiometry (DXA) was used to assess and measure aBMD of the lumbar spine. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
          <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="-0.21" upper_limit="1.68"/>
                    <measurement group_id="O2" value="1.50" lower_limit="0.53" upper_limit="2.48"/>
                    <measurement group_id="O3" value="0.92" lower_limit="-0.02" upper_limit="1.87"/>
                    <measurement group_id="O4" value="1.69" lower_limit="0.73" upper_limit="2.64"/>
                    <measurement group_id="O5" value="1.13" lower_limit="0.18" upper_limit="2.08"/>
                    <measurement group_id="O6" value="0.57" lower_limit="-0.40" upper_limit="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.749</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons for the areal BMD at lumbar spine endpoint were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>2.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.333</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons for the areal BMD at lumbar spine endpoint were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>2.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.823</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons for the areal BMD at lumbar spine endpoint were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.14</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.457</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons for the areal BMD at lumbar spine endpoint were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>2.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.823</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons for the areal BMD at lumbar spine endpoint were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.17</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Total Serum Calcium Levels Outside the Pre-defined Limits of Change</title>
        <description>Normal serum calcium level is 8-10 mg/dL (2-2.5 mmol/L) with some interlaboratory variation in the reference range, and hypercalcemia is defined as a serum calcium level greater than 10.5 mg/dL (&gt;2.5 mmol/L).
Based on these references, ≥10.6 mg/dL was predefined in this study as the cut-off for the normal limits of change. Participants with calcium levels ≥10.6 mg/dL were considered as having a &quot;Tier 1&quot; safety event.</description>
        <time_frame>Baseline through Month 6</time_frame>
        <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment. 3 randomized participants did not receive treatment and were not included in the APaT.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Total Serum Calcium Levels Outside the Pre-defined Limits of Change</title>
          <description>Normal serum calcium level is 8-10 mg/dL (2-2.5 mmol/L) with some interlaboratory variation in the reference range, and hypercalcemia is defined as a serum calcium level greater than 10.5 mg/dL (&gt;2.5 mmol/L).
Based on these references, ≥10.6 mg/dL was predefined in this study as the cut-off for the normal limits of change. Participants with calcium levels ≥10.6 mg/dL were considered as having a &quot;Tier 1&quot; safety event.</description>
          <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment. 3 randomized participants did not receive treatment and were not included in the APaT.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="32.3"/>
                    <measurement group_id="O3" value="32.8"/>
                    <measurement group_id="O4" value="56.3"/>
                    <measurement group_id="O5" value="73.0"/>
                    <measurement group_id="O6" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>69.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>56.5</ci_lower_limit>
            <ci_upper_limit>80.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>53.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>39.6</ci_lower_limit>
            <ci_upper_limit>65.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>29.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.6</ci_lower_limit>
            <ci_upper_limit>42.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>29.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.0</ci_lower_limit>
            <ci_upper_limit>42.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.254</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>14.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Albumin-Corrected Calcium Levels Outside the Pre-defined Limits of Change</title>
        <description>Albumin-Corrected Calcium = ([4 - plasma albumin in g/dL] × 0.8 + serum calcium).
≥10.6 mg/dL was predefined in this study as the cut-off for the normal limits of change. Participants with albumin-corrected calcium levels ≥10.6 mg/dL were considered as having a &quot;Tier 1&quot; safety event.</description>
        <time_frame>Baseline through Month 6</time_frame>
        <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment. 3 randomized participants did not receive treatment and were not included in the APaT.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Albumin-Corrected Calcium Levels Outside the Pre-defined Limits of Change</title>
          <description>Albumin-Corrected Calcium = ([4 - plasma albumin in g/dL] × 0.8 + serum calcium).
≥10.6 mg/dL was predefined in this study as the cut-off for the normal limits of change. Participants with albumin-corrected calcium levels ≥10.6 mg/dL were considered as having a &quot;Tier 1&quot; safety event.</description>
          <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment. 3 randomized participants did not receive treatment and were not included in the APaT.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="9.7" lower_limit="2.96" upper_limit="5.35"/>
                    <measurement group_id="O3" value="18.8" lower_limit="2.75" upper_limit="5.09"/>
                    <measurement group_id="O4" value="37.5" lower_limit="4.28" upper_limit="6.69"/>
                    <measurement group_id="O5" value="49.2" lower_limit="5.10" upper_limit="7.50"/>
                    <measurement group_id="O6" value="1.6" lower_limit="-1.04" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>47.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34.9</ci_lower_limit>
            <ci_upper_limit>60.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>35.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.1</ci_lower_limit>
            <ci_upper_limit>48.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.7</ci_lower_limit>
            <ci_upper_limit>28.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>18.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.313</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.5</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Kidney Stones</title>
        <description>Evidence of kidney stone(s) was considered an event of interest and was prespecified as a &quot;Tier 1&quot; safety event.</description>
        <time_frame>Baseline through Month 6</time_frame>
        <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment. 3 randomized participants did not receive treatment and were not included in the APaT.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Kidney Stones</title>
          <description>Evidence of kidney stone(s) was considered an event of interest and was prespecified as a &quot;Tier 1&quot; safety event.</description>
          <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment. 3 randomized participants did not receive treatment and were not included in the APaT.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.313</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The Miettinen and Nurminen Method was used to estimate the treatment differences between the active dose group and the placebo group by comparing the percentage of participants in the active dose group with the event vs. the percentage of participants in the placebo group with the event. An associated p-value and 95% confidence interval were calculated for this difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.321</p_value>
            <method>Miettinen and Nurminen Method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Bone Neoplasms</title>
        <description>Evidence of bone neoplasm(s) was considered an event of interest and was prespecified as a &quot;Tier 1&quot; safety event.</description>
        <time_frame>Baseline through Month 6</time_frame>
        <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment. 3 randomized participants did not receive treatment and were not included in the APaT.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Bone Neoplasms</title>
          <description>Evidence of bone neoplasm(s) was considered an event of interest and was prespecified as a &quot;Tier 1&quot; safety event.</description>
          <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment. 3 randomized participants did not receive treatment and were not included in the APaT.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Percent Change From Baseline to Month 6 in Total Hip aBMD</title>
        <description>DXA was used to assess and measure aBMD of the total hip. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Percent Change From Baseline to Month 6 in Total Hip aBMD</title>
          <description>DXA was used to assess and measure aBMD of the total hip. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
          <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" lower_limit="-0.95" upper_limit="0.55"/>
                    <measurement group_id="O2" value="-0.32" lower_limit="-1.10" upper_limit="0.46"/>
                    <measurement group_id="O3" value="0.32" lower_limit="-0.43" upper_limit="1.07"/>
                    <measurement group_id="O4" value="0.07" lower_limit="-0.69" upper_limit="0.82"/>
                    <measurement group_id="O5" value="0.33" lower_limit="-0.43" upper_limit="1.08"/>
                    <measurement group_id="O6" value="0.08" lower_limit="-0.69" upper_limit="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.959</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.971</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.959</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.95</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.915</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.78</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.959</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.60</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Percent Change From Baseline to Month 6 in Femoral Neck aBMD</title>
        <description>DXA was used to assess and measure aBMD of the femoral neck. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Percent Change From Baseline to Month 6 in Femoral Neck aBMD</title>
          <description>DXA was used to assess and measure aBMD of the femoral neck. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
          <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.21" upper_limit="2.25"/>
                    <measurement group_id="O2" value="-0.52" lower_limit="-1.58" upper_limit="0.54"/>
                    <measurement group_id="O3" value="0.12" lower_limit="-0.89" upper_limit="1.14"/>
                    <measurement group_id="O4" value="-0.20" lower_limit="-1.23" upper_limit="0.83"/>
                    <measurement group_id="O5" value="0.54" lower_limit="-0.48" upper_limit="1.56"/>
                    <measurement group_id="O6" value="-0.04" lower_limit="-1.09" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.849</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.964</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.79</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.964</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.27</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.855</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.23</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.287</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Percent Change From Baseline to Month 6 in Trochanter aBMD</title>
        <description>DXA was used to assess and measure aBMD of the trochanter. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Percent Change From Baseline to Month 6 in Trochanter aBMD</title>
          <description>DXA was used to assess and measure aBMD of the trochanter. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
          <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="-0.78" upper_limit="1.60"/>
                    <measurement group_id="O2" value="0.95" lower_limit="-0.29" upper_limit="2.19"/>
                    <measurement group_id="O3" value="0.54" lower_limit="-0.65" upper_limit="1.74"/>
                    <measurement group_id="O4" value="0.49" lower_limit="-0.72" upper_limit="1.70"/>
                    <measurement group_id="O5" value="1.10" lower_limit="-0.11" upper_limit="2.30"/>
                    <measurement group_id="O6" value="0.49" lower_limit="-0.74" upper_limit="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.933</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.56</ci_lower_limit>
            <ci_upper_limit>2.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.69</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.84</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.959</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.67</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.10</ci_lower_limit>
            <ci_upper_limit>1.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Percent Change From Baseline to Month 6 in Total Body aBMD</title>
        <description>DXA was used to assess and measure aBMD of the total body. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Percent Change From Baseline to Month 6 in Total Body aBMD</title>
          <description>DXA was used to assess and measure aBMD of the total body. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
          <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" lower_limit="-0.11" upper_limit="0.97"/>
                    <measurement group_id="O2" value="0.28" lower_limit="-0.28" upper_limit="0.84"/>
                    <measurement group_id="O3" value="0.80" lower_limit="0.27" upper_limit="1.33"/>
                    <measurement group_id="O4" value="0.21" lower_limit="-0.35" upper_limit="0.76"/>
                    <measurement group_id="O5" value="0.09" lower_limit="-0.44" upper_limit="0.63"/>
                    <measurement group_id="O6" value="0.27" lower_limit="-0.29" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.976</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.982</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.489</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.982</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.976</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Percent Change From Baseline to Month 6 in Distal One-third Forearm Areal BMD</title>
        <description>DXA was used to assess and measure aBMD of the distal 1/3 forearm. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Percent Change From Baseline to Month 6 in Distal One-third Forearm Areal BMD</title>
          <description>DXA was used to assess and measure aBMD of the distal 1/3 forearm. Areal BMD was measured as &quot;areal&quot; density using units of gram (gm) of tissue /centimeter of tissue squared (cm^2).</description>
          <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" lower_limit="-1.42" upper_limit="0.48"/>
                    <measurement group_id="O2" value="-0.32" lower_limit="-1.30" upper_limit="0.65"/>
                    <measurement group_id="O3" value="0.44" lower_limit="-0.47" upper_limit="1.36"/>
                    <measurement group_id="O4" value="-0.49" lower_limit="-1.46" upper_limit="0.48"/>
                    <measurement group_id="O5" value="-0.56" lower_limit="-1.50" upper_limit="0.37"/>
                    <measurement group_id="O6" value="-0.21" lower_limit="-1.18" upper_limit="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.961</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.00</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.961</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.90</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.778</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>2.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.961</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.45</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.961</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.77</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Percent Change From Baseline to Month 6 in Trabecular Volumetric BMD of the Hip</title>
        <description>Quantitative computed tomography (QCT) technology was used to assess and measure bone mineral content volumetrically (ie, in grams of tissue per centimeter of tissue cubed).</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Percent Change From Baseline to Month 6 in Trabecular Volumetric BMD of the Hip</title>
          <description>Quantitative computed tomography (QCT) technology was used to assess and measure bone mineral content volumetrically (ie, in grams of tissue per centimeter of tissue cubed).</description>
          <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" lower_limit="-1.44" upper_limit="0.62"/>
                    <measurement group_id="O2" value="-0.34" lower_limit="-1.43" upper_limit="0.75"/>
                    <measurement group_id="O3" value="-0.89" lower_limit="-1.90" upper_limit="0.13"/>
                    <measurement group_id="O4" value="-0.88" lower_limit="-1.97" upper_limit="0.22"/>
                    <measurement group_id="O5" value="-0.80" lower_limit="-1.87" upper_limit="0.26"/>
                    <measurement group_id="O6" value="-0.37" lower_limit="-1.37" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.901</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.03</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.901</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.901</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.17</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.997</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.29</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.997</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.51</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Percent Change From Baseline to Month 6 in Trabecular Volumetric BMD of the Lumbar Spine</title>
        <description>Quantitative computed tomography (QCT) technology was used at baseline and periodically through out the study to assess and measure bone mineral content volumetrically (ie, in grams of tissue per centimeter of tissue cubed).</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Percent Change From Baseline to Month 6 in Trabecular Volumetric BMD of the Lumbar Spine</title>
          <description>Quantitative computed tomography (QCT) technology was used at baseline and periodically through out the study to assess and measure bone mineral content volumetrically (ie, in grams of tissue per centimeter of tissue cubed).</description>
          <population>Full Analysis Set (FAS); participants who received at least one dose of study treatment, had post-randomization data subsequent to at least one dose of study treatment, and who had baseline data.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" lower_limit="0.13" upper_limit="3.75"/>
                    <measurement group_id="O2" value="0.94" lower_limit="-0.97" upper_limit="2.85"/>
                    <measurement group_id="O3" value="1.83" lower_limit="0.02" upper_limit="3.64"/>
                    <measurement group_id="O4" value="3.35" lower_limit="1.43" upper_limit="5.27"/>
                    <measurement group_id="O5" value="1.06" lower_limit="-0.83" upper_limit="2.96"/>
                    <measurement group_id="O6" value="1.43" lower_limit="-0.33" upper_limit="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.979</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.73</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.363</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>1.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>4.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.979</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>2.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.979</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.27</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.979</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.34</ci_lower_limit>
            <ci_upper_limit>3.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Percent Change From Baseline to Month 6 in the Ratio of Urinary N-Telopeptides of Type I Collagen to Creatinine (u-NTx/Cr)</title>
        <description>The ratio of u-NTx to Cr is a biomarker for bone resorption. It is measured in the serum in units of nanomoles (nm) of bone collagen equivalents (BCE)/millimoles of creatinine (Cr).</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Per Protocol population; defined as the subset of the APaT population that excluded participants based on critical protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Percent Change From Baseline to Month 6 in the Ratio of Urinary N-Telopeptides of Type I Collagen to Creatinine (u-NTx/Cr)</title>
          <description>The ratio of u-NTx to Cr is a biomarker for bone resorption. It is measured in the serum in units of nanomoles (nm) of bone collagen equivalents (BCE)/millimoles of creatinine (Cr).</description>
          <population>Per Protocol population; defined as the subset of the APaT population that excluded participants based on critical protocol violations.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.18" lower_limit="-21.23" upper_limit="-2.10"/>
                    <measurement group_id="O2" value="-9.46" lower_limit="-18.87" upper_limit="1.03"/>
                    <measurement group_id="O3" value="-20.73" lower_limit="-28.79" upper_limit="-11.76"/>
                    <measurement group_id="O4" value="-7.82" lower_limit="-17.33" upper_limit="2.78"/>
                    <measurement group_id="O5" value="1.87" lower_limit="-8.53" upper_limit="13.45"/>
                    <measurement group_id="O6" value="-17.90" lower_limit="-26.15" upper_limit="-8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>19.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.26</ci_lower_limit>
            <ci_upper_limit>37.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.357</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>10.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.16</ci_lower_limit>
            <ci_upper_limit>26.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.642</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-2.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.81</ci_lower_limit>
            <ci_upper_limit>9.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.434</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>8.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.09</ci_lower_limit>
            <ci_upper_limit>24.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.579</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>5.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.62</ci_lower_limit>
            <ci_upper_limit>20.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Percent Change From Baseline to Month 6 in Serum C-Terminal Telopeptide Collagen I (s-CTx)</title>
        <description>C-Terminal Telopeptide Collagen I is used as a serum-marker of bone resorption in the assessment of osteoporosis.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>Per Protocol population; defined as the subset of the APaT population that excluded participants based on critical protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Percent Change From Baseline to Month 6 in Serum C-Terminal Telopeptide Collagen I (s-CTx)</title>
          <description>C-Terminal Telopeptide Collagen I is used as a serum-marker of bone resorption in the assessment of osteoporosis.</description>
          <population>Per Protocol population; defined as the subset of the APaT population that excluded participants based on critical protocol violations.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.39" lower_limit="-23.80" upper_limit="-6.05"/>
                    <measurement group_id="O2" value="-5.87" lower_limit="-15.32" upper_limit="4.63"/>
                    <measurement group_id="O3" value="-4.93" lower_limit="-14.23" upper_limit="5.39"/>
                    <measurement group_id="O4" value="5.68" lower_limit="-4.77" upper_limit="17.27"/>
                    <measurement group_id="O5" value="19.37" lower_limit="7.60" upper_limit="32.43"/>
                    <measurement group_id="O6" value="-14.89" lower_limit="-23.24" upper_limit="-5.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>34.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.27</ci_lower_limit>
            <ci_upper_limit>53.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>20.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.28</ci_lower_limit>
            <ci_upper_limit>38.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.307</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>9.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.69</ci_lower_limit>
            <ci_upper_limit>25.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.307</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>9.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.85</ci_lower_limit>
            <ci_upper_limit>23.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.937</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.92</ci_lower_limit>
            <ci_upper_limit>11.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Percent Change From Baseline to Month 6 in Serum Bone-Specific Alkaline Phosphatase (s-BSAP)</title>
        <description>Bone Specific Alkaline Phosphatase is a biomarker of bone formation and is measured in units of microgram (μg)/liter (L).</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Per Protocol population; defined as the subset of the APaT population that excluded participants based on critical protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Percent Change From Baseline to Month 6 in Serum Bone-Specific Alkaline Phosphatase (s-BSAP)</title>
          <description>Bone Specific Alkaline Phosphatase is a biomarker of bone formation and is measured in units of microgram (μg)/liter (L).</description>
          <population>Per Protocol population; defined as the subset of the APaT population that excluded participants based on critical protocol violations.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" lower_limit="-6.87" upper_limit="6.10"/>
                    <measurement group_id="O2" value="0.26" lower_limit="-6.17" upper_limit="7.13"/>
                    <measurement group_id="O3" value="4.39" lower_limit="-2.13" upper_limit="11.35"/>
                    <measurement group_id="O4" value="17.33" lower_limit="9.93" upper_limit="25.22"/>
                    <measurement group_id="O5" value="13.13" lower_limit="6.02" upper_limit="20.72"/>
                    <measurement group_id="O6" value="-6.05" lower_limit="-11.92" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>19.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.42</ci_lower_limit>
            <ci_upper_limit>31.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>23.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.02</ci_lower_limit>
            <ci_upper_limit>35.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.061</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>10.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>21.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.283</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>6.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.81</ci_lower_limit>
            <ci_upper_limit>16.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.283</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>5.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.39</ci_lower_limit>
            <ci_upper_limit>14.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Percent Change From Baseline to Month 6 in Serum Procollagen Type I N-Terminal Propeptide (P1NP)</title>
        <description>Measurement of P1NP appears to be a sensitive marker of bone formation rate in the assessment of osteoporosis.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>The 'Per Protocol' population was used for this analysis. The Per-Protocol population was defined as a subset population that excluded participants based on critical protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Percent Change From Baseline to Month 6 in Serum Procollagen Type I N-Terminal Propeptide (P1NP)</title>
          <description>Measurement of P1NP appears to be a sensitive marker of bone formation rate in the assessment of osteoporosis.</description>
          <population>The 'Per Protocol' population was used for this analysis. The Per-Protocol population was defined as a subset population that excluded participants based on critical protocol violations.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.97" lower_limit="-18.46" upper_limit="-0.59"/>
                    <measurement group_id="O2" value="-9.76" lower_limit="-18.36" upper_limit="-0.26"/>
                    <measurement group_id="O3" value="2.33" lower_limit="-7.16" upper_limit="12.78"/>
                    <measurement group_id="O4" value="21.30" lower_limit="9.91" upper_limit="33.88"/>
                    <measurement group_id="O5" value="38.41" lower_limit="25.45" upper_limit="52.71"/>
                    <measurement group_id="O6" value="-18.36" lower_limit="-25.96" upper_limit="-9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>56.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.62</ci_lower_limit>
            <ci_upper_limit>76.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>39.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.44</ci_lower_limit>
            <ci_upper_limit>57.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>20.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.72</ci_lower_limit>
            <ci_upper_limit>35.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.265</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>8.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.81</ci_lower_limit>
            <ci_upper_limit>22.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.265</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>8.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.40</ci_lower_limit>
            <ci_upper_limit>20.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Percent Change From Baseline to Month 6 in Serum Osteocalcin</title>
        <description>Serum osteocalcin is a biomarker of bone formation and is measured using units of nanograms (ng) / milliliter (mL).</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Per Protocol population; defined as the subset of the APaT population that excluded participants based on critical protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5442 2.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>MK-5442 5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>MK-5442 7.5 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O4">
            <title>MK-5442 10 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O5">
            <title>MK-5442 15 mg</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Percent Change From Baseline to Month 6 in Serum Osteocalcin</title>
          <description>Serum osteocalcin is a biomarker of bone formation and is measured using units of nanograms (ng) / milliliter (mL).</description>
          <population>Per Protocol population; defined as the subset of the APaT population that excluded participants based on critical protocol violations.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.61" lower_limit="-18.19" upper_limit="-4.50"/>
                    <measurement group_id="O2" value="-2.75" lower_limit="-10.10" upper_limit="5.19"/>
                    <measurement group_id="O3" value="9.18" lower_limit="1.15" upper_limit="17.86"/>
                    <measurement group_id="O4" value="25.79" lower_limit="16.45" upper_limit="35.88"/>
                    <measurement group_id="O5" value="37.43" lower_limit="27.24" upper_limit="48.42"/>
                    <measurement group_id="O6" value="-15.62" lower_limit="-21.83" upper_limit="-8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>53.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.83</ci_lower_limit>
            <ci_upper_limit>68.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>41.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.36</ci_lower_limit>
            <ci_upper_limit>55.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>24.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.39</ci_lower_limit>
            <ci_upper_limit>37.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>12.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.73</ci_lower_limit>
            <ci_upper_limit>24.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.397</p_value>
            <p_value_desc>The Type-I error rate over the multiple treatment dose comparisons were controlled by step-down Dunnett’s test at the primary time point of Month 6, at an alpha level of 0.05, two-sided.</p_value_desc>
            <method>Longitudinal Data Analysis Model</method>
            <param_type>LS Mean Difference in Change From BL</param_type>
            <param_value>4.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.31</ci_lower_limit>
            <ci_upper_limit>13.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From October 2, 2009 to December 21, 2010, with an in-house data-cut date of February 10, 2011</time_frame>
      <desc>All Participants as Treated (APaT) Population. Three participants were randomized but not treated, and thus are not included in the adverse event table calculations (one participant was randomized to 5 mg MK-5442; one participant was randomized to 15 mg MK-5442 and one participant was randomized to Placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-5442 2.5 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="E2">
          <title>MK-5442 5 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="E3">
          <title>MK-5442 7.5 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="E4">
          <title>MK-5442 10 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="E5">
          <title>MK-5442 15 mg</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Ischaemic heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 14.0">Paroxysmal atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>External haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis of leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Coronary stent stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture malunion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Breast cancer stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Gallbladder carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Postural hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.05</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="63"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chest Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Common Cold</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Hip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Subsequent to the multicenter publication, or 24 months after completion of the study, whichever comes first, an investigator and/or his/her colleagues may publish the results of the study associated with their study site independently.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp and Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

